Fifth Third Bancorp bought a new stake in Palvella Therapeutics, Inc. (NASDAQ: PVLA) in the undefine

US stocks rise, Nasdaq gains 1%. Hasbro Inc (HAS) up 8.6% on strong Q2 results and raised sales guid

Brings more than 25 years of experience advancing and commercializing high-impact therapies for seri

FDA’s rolling review process is intended to facilitate expedited review, enabling FDA to begin evalu

FDA's rolling review process is intended to facilitate expedited review, enabling FDA to begin evalu

4,302 common shares were exercised and sold on June 17, 2026, for $476,000 at a weighted average pri

FDA’s rolling review process is intended to facilitate expedited review, enabling FDA to begin evalu

FDA's rolling review process is intended to facilitate expedited review, enabling FDA to begin evalu

Palvella Therapeutics, Inc. (PVLA) Presents at Goldman Sachs 47th Annual Global Healthcare Conferenc

Palvella Therapeutics is now a much more credible bet on QTORIN after their positive mLM data. They'

Palvella remains on track to submit an NDA in the second half of 2026Microcystic lymphatic malformat

Palvella remains on track to submit an NDA in the second half of 2026 Microcystic lymphatic malforma

WAYNE, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”

Palvella Therapeutics, Inc. (Palvella or the "Company") (NASDAQ:PVLA), a clinical-stage biop

Yale-licensed U.S. patent provides broad protection for topical mevalonate pathway inhibition in por

Stephens & Co. analyst Sudan Loganathan reiterates Palvella Therapeutics (NASDAQ:PVLA) with a

WAYNE, Pa., May 21, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or “the Company”)

In SELVA Phase 3 study, 100% of participants (13/13) aged 6–11 years were rated as "Much Improve

In SELVA Phase 3 study, 100% of participants (13/13) aged 6-11 years were rated as "Much Improved" (

100% of patients with bleeding at baseline demonstrated a statistically significant improvement on t

100% of patients with bleeding at baseline demonstrated a statistically significant improvement on t

The transfer is effective at the opening of trading on Wednesday, May 13, 2026. The Company's co

Uplisting reflects Palvella's continued progress advancing potential first-in-disease therapies for

Stephens & Co. analyst Sudan Loganathan initiates coverage on Palvella Therapeutics (NASDAQ:P

Palvella Therapeutics NASDAQ: PVLA said it remains on track to submit a New Drug Application in the

Palvella Therapeutics, Inc. (PVLA) Q1 2026 Earnings Call Transcript

Palvella Therapeutics (NASDAQ:PVLA) reported quarterly losses of $(1.20) per share which missed the

FDA Pre-New Drug Application (NDA) meeting granted for QTORIN™ rapamycin for the treatment of microc

Clinically significant angiokeratomas represent a rare, chronic and debilitating lymphatic malformat

Clinically significant angiokeratomas represent a rare, chronic and debilitating lymphatic malformat

WAYNE, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or “the Company

James Treat, MD, Professor of Clinical Pediatrics and Dermatology at the Children's Hospital of

Chardan Capital analyst Geulah Livshits maintains Palvella Therapeutics (NASDAQ:PVLA) with a Buy

Palvella Therapeutics (NASDAQ:PVLA) reported quarterly losses of $(1.08) per share which missed the

Palvella Therapeutics, Inc. (Palvella or "the Company") (Nasdaq: PVLA), a clinical-stage bio

HC Wainwright & Co. analyst Andrew S. Fein maintains Palvella Therapeutics (NASDAQ:PVLA) with

Patent strengthens global intellectual property protection for QTORIN™ rapamycin, Palvella's lea

Mizuho analyst Graig Suvannavejh maintains Palvella Therapeutics (NASDAQ:PVLA) with a Outperform

BTIG analyst Jeet Mukherjee maintains Palvella Therapeutics (NASDAQ:PVLA) with a Buy and raises

Palvella Therapeutics, Inc. ("Palvella") (Nasdaq: PVLA), a clinical-stage biopharmaceutical

Chardan Capital analyst Geulah Livshits maintains Palvella Therapeutics (NASDAQ:PVLA) with a Buy

HC Wainwright & Co. analyst Andrew S. Fein maintains Palvella Therapeutics (NASDAQ:PVLA) with

Palvella Therapeutics shares are trading higher after reporting topline data from its Phase 3 SELVA